Related Experiment Video
Updated: May 25, 2026
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
Yeast surface display-based screening and preliminary characterization of nectin-4-targeting nanobodies for bladder
Jianhua Wen1, Liangyi Wei1, Jun Huang2
1Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Background:
Advanced bladder cancer (BCa) is associated with a poor prognosis, highlighting the urgent need for novel therapeutic strategies with improved efficacy and reduced toxicity. Nectin-4 (PVRL4, here after referred to as N4) is a clinically validated therapeutic target; however, existing antibody-based agents are limited by inadequate tumor penetration and off-target toxicities. Nanobodies (Nbs) possess favorable characteristics, including small molecular size, enhanced tissue penetration, and ease of sengineering. This study aimed to identify and preliminarily characterize N4-targeting Nb candidates for BCa using a yeast surface display-based screening strategy.
Results:
N4 was highly expressed in BCa and significantly associated with an unfavorable prognosis. The YSD platform supported efficient library expansion, surface display, and iterative enrichment of N4-binding clones. Among the identified Nbs, Nb-80 exhibited apparent binding activity, with an EC₅₀ of 0.150 μg/mL. BLI analysis demonstrated rapid association-dissociation kinetics.
Conclusions:
An N4-binding Nb candidate was identified and preliminarily characterized using a YSD-based screening strategy. These findings support the utility of the YSD platform for Nb discovery and provide a preliminary basis for further validation of N4-targeting Nb candidates in BCa.
Clinical Trial Number:
Not applicable.
Insights
Researchers identified a novel nanobody targeting Nectin-4 for advanced bladder cancer. This promising candidate shows potential for improved tumor penetration and reduced toxicity compared to existing therapies.
Area of Science:
- Oncology
- Biotechnology
- Immunotherapy
Background:
- Advanced bladder cancer (BCa) presents a poor prognosis, necessitating novel therapeutics.
- Nectin-4 (N4) is a validated target, but current antibody therapies face challenges with tumor penetration and toxicity.
- Nanobodies (Nbs) offer advantages like small size and enhanced tissue penetration for targeted therapies.
Purpose of the Study:
- To identify and characterize Nectin-4 (N4)-targeting nanobody (Nb) candidates for bladder cancer (BCa).
- To evaluate the potential of nanobodies as an alternative to antibody-based therapies for BCa.
Main Methods:
- Utilized a yeast surface display (YSD) platform for screening and enrichment of N4-binding clones.
- Iterative library expansion and surface display were employed for efficient candidate selection.
- Preliminary characterization included binding activity assessment (EC₅₀) and kinetics analysis (BLI).
Main Results:
- Nectin-4 (N4) expression was high in bladder cancer (BCa) and correlated with poor prognosis.
- The yeast surface display (YSD) platform enabled efficient N4-binding nanobody (Nb) identification.
- Nb-80 demonstrated significant binding activity (EC₅₀ = 0.150 μg/mL) with rapid association-dissociation kinetics.
Conclusions:
- A Nectin-4 (N4)-binding nanobody (Nb) candidate was successfully identified and characterized using yeast surface display (YSD).
- The YSD platform is effective for nanobody discovery.
- These findings provide a foundation for further development of N4-targeting nanobodies for bladder cancer (BCa) treatment.
